Nasdaq

New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma

Kite, a Gilead Company, today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus™ in adult patients with relapsed or refractory mantle cell lymphoma. At a median follow-up of 17.5 ...
Nasdaq

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers

ZUMA-2 is a single-arm, international multicenter (US and Europe), open-label Phase 2 study involving 74 enrolled/leukapheresed adult patients (≥18 years old) with MCL whose disease is refractory to ...
Business Wire

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus ® in Patients With Aggressive Blood Cancers

– At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-Term Response in Adult Patients with Relapsed/Refractory (R/R) Mantle Cell ...
Healio

VIDEO: Expert discusses SHINE, ZUMA-2 trials for mantle cell lymphoma

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...